Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: Comparison with the activities of 14 other agents

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 9, 1999, Pages 2320-2322

  Betriu, Carmen ^a   Gómez, María ^a   Palau, M Luisa ^a   Sánchez, Ana ^a   Picazo, Juan J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEFMINOX; CEFOXITIN; CEFTIZOXIME; CHLORAMPHENICOL; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SANFETRINEM; SULBACTAM; TICARCILLIN; TIMENTIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEROIDES FRAGILIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0344562869     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.9.2320     Document Type: Article

References (20)

1. Aldridge, K. E., M. Gelfand, L. B. Reller, L. W. Ayers, C. L. Pierson, F. Schoenknecht, R. C. Tilton, J. Wilkins, A. Henderberg, D. D. Schiro, M. Johnson, A. Janney, and C. V. Sanders. 1994. A five-year multicenler study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin and metronidazole in the United States. Diagn. Microbiol. Infect. Dis. 18:235-241.
2. Aldridge, K. E., and D. S. Ashcraft. 1997. Comparison of the in vitro activities of Bay-128039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. 41:709-711.
3. Appelbaum, P. C., S. K. Spangler, and M. R. Jacobs. 1993. Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J. Antimicrob. Chemother. 32:223-231.
4. Babini, G. S., M. Yuan, and D. M. Livermore. 1998. Interactions of β-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral β-lactams. Antimicrob. Agents Chemother. 42:1168-1175.
5. Bandoh, K., K. Ueno, K. Watanabe, and N. Kato. 1993. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin. Infect. Dis. 16(Suppl. 4):S382-S386.
6. Baquero, F., and M. Reig. 1992. Resistance of anaerobic bacteria to antimicrobial agents in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 11:1016-1020.
7. Betriu, C., C. Cabronero, M. Gómez, and J. J. Picazo. 1992. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989. Eur. J. Clin. Microbiol. Infect. Dis. 11:352-356.
8. Betriu, C., A. Sánchez, M. Gómez, M. L. Palau, and J. J. Picazo. 1999. In-vitro susceptibilities of the Bacteroides fragilis group to newer β-lactam agents. I. Antimicrob. Chemother. 43:133-136.
9. Di Modugno, E., R. Broggio, I. Erbetti, and J. Lowther. 1997. In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem. Antimicrob. Agents Chemother. 41:2742-2748.
10. Dubreuil, L. 1996. Bacteroides fragilis: état de la sensibilité aux antibiotiques, évolution des résistances. Med. Mal. Infect. 26:196-207.
11. Edlund, C., S. Sabouri, and C. E. Nord. 1998. Comparative in vitro activity of Bay 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 17:193-195.
12. García-Rodríguez, J. A., J. E. García-Sánchez, and J. L. Muñoz-Bellido. 1995. Antimicrobial resistance in anaerobic bacteria: current situation. Anaerobe 1:69-80.
13. Hoellman, D. B., S. K. Spangler, M. R. Jacobs, and P. C. Appelbaum. 1998. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds. Antimicrob. Agents Chemother. 42:495-501.
14. MacGowan, A. P., K. E. Bowker, H. A. Holt, M. Wootton, and D. S. Reeves. 1997. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J. Antimicrob. Chemother. 40:503-509.
15. National Committee for Clinical laboratory Standards. 1993. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd ed. Approved standard. NCCLS publication M11-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Nord, C. E., A. Lindmark, and J. Persson. 1989. Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 8:1064-1067.
17. Snydman, D. R., and L. McDermott. 1996. Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species. Infect. Dis. Clin. Pract. 5(Suppl. 3):S96-S100.
18. Snydman, D. R., L. McDermott, G. J. Cuchural, Jr, D. W. Hecht, P. B. Iannini, L. J. Harrell, S. G. Jenkins, J. P. O'Keefe, C. L. Pierson, J. D. Rihs, V. L. Yu, S. M. Finegold, and S. L. Gorbach. 1996. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin. Infect. Dis. 23(Suppl. 1):S54-S65.
19. Turgeon, P., V. Turgeon, M. Gourdeau, J. Dubois, and F. Lamothe. 1994. Longitudinal study of susceptibilities of the Bacteroides fragilis group to five antimicrobial agents in three medical centers. Antimicrob. Agents Chemother. 38:2276-2279.
20. Wexler, H. M., E. Molitoris, D. Molitoris, and S. M. Finegold. 1996. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob. Agents Chemother. 40:2232-2235.